Yorktown Management & Research CO Inc Jounce Therapeutics, Inc. Transaction History

Yorktown Management & Research CO Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 29, 2022	SELL	$6.01 - $8.54 $825,173 - $1.17 Million	-137,300 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$7.11 - $9.64 $171,351 - $232,324	24,100 Added 21.29%	137,300 $1.15 Million
Q3 2021 Nov 04, 2021	BUY	$5.04 - $8.73 $285,264 - $494,118	56,600 Added 100.0%	113,200 $841,000
Q2 2021 Aug 03, 2021	BUY	$6.58 - $10.66 $48,692 - $78,884	7,400 Added 15.04%	56,600 $385,000
Q4 2020 Feb 11, 2021	SELL	$6.37 - $10.33 $12,740 - $20,660	-2,000 Reduced 3.91%	49,200 $344,000
Q3 2020 Nov 06, 2020	BUY	$4.58 - $10.95 $37,556 - $89,790	8,200 Added 19.07%	51,200 $418,000
Q2 2020 Aug 11, 2020	BUY	$4.17 - $7.58 $179,310 - $325,940	43,000 New	43,000 $297,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Yorktown Management & Research CO Inc, based on Form 13F filings with the SEC.

Stay updated on Yorktown Management & Research CO Inc with notifications on news.